NCT05041790View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment

PHASE4UnknownINTERVENTIONAL
Enrollment

418

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions
Mild Cognitive Impairment
Interventions
DRUG

Choline Alfoscerate

Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.

DRUG

Placebo

Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.

Trial Locations (1)

Unknown

Asan Medical Center Institutional Review Board, Seoul

Sponsors
All Listed Sponsors
collaborator

Choline Alfoscerate Re-evaluation Consortium (57 pharmaceutical companies)

UNKNOWN

lead

Chong Kun Dang Pharmaceutical

INDUSTRY